5-HT-receptorantagonisten als vervangers van metoclopramide en domperidon

Objective

To investigate whether the anti-emetics metoclopramide and domperidone can be replaced by 5-HT₃-antagonists, as side effects restrict use of these dopamine antagonists.

Design

Systematic review.

Method

We searched the Embase and PubMed databases for articles published in the period 1995-October 2015, in which the efficacy or side effects of metoclopramide or domperidone were compared with at least one of the 5-HT₃-antagonists ondansetron, granisetron, tropisetron or palonosetron. These had to be randomised controlled clinical studies into the known indications for metoclopramide and domperidone for prevention and treatment of nausea and vomiting. Two reviewers independently selected articles based on the title and abstract, then assessed for eligibility based on the full texts.

Results

In total, 56 articles were included in this review. The conclusion in 51 studies was that the efficacy of 5-HT₃-antagonists in nausea and vomiting is comparable or even superior to that of metoclopramide. Metoclopramide more often caused extrapyramidal side effects; 5-HT₃-antagonists were more likely to cause headaches and constipation. The majority of the studies compared metoclopramide with ondansetron. None of the articles studied palonosetron, and only one study compared domperidone with a 5-HT₃-antagonist.

Conclusion

We found enough evidence to presume that metoclopramide can be replaced by 5-HT₃-antagonists for preventing delayed chemotherapy-induced nausea and vomiting and for prophylaxis or treatment of postoperative nausea and vomiting. More research is needed into the other indications and into the substitutability of domperidone.

Conflict of interest and financial support: none declared.